WDNAWisdomTree BioRevolution Fund
Tracks the price and yield performance of the WisdomTree BioRevolution Index.
By WisdomTree · Launched 2021
Annual Cost
0.45%
#2,319 of 6,040 · average
Fund Size
$3M
#5,437 of 6,040 · small
Return (1Y)
+65.4%
Track Record
5 years
#2,347 of 6,040 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$16,028+60.3%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
GlobalStrategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
WisdomTree BioRevolution Index
Holdings
By weightConcentration
Top 10 holdings = 27.9% of funddiversified
Moderna Inc
4.5%
Johnson & Johnson
3.2%
United Therapeutics Corporation
2.8%
Pfizer Inc.
2.7%
Eli Lilly & Co.
2.6%
Stoke Therapeutics Inc
2.5%
NATERA INC
2.5%
Amgen Inc.
2.3%
Twist Bioscience Corporation
2.3%
AstraZeneca PLC
2.3%
Asset allocation
Stocks
99.9%
Cash
0.1%
By sector
Healthcare
90.0%
Basic Materials
6.1%
Consumer Defensive
3.9%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
28.3%High
Year-on-year price swings
Max drawdown
-58.9%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.51Decent risk-adjusted returns
Sortino (3Y)
0.77Moderate downside risk
Listing
- Exchange
- Cboe BZX
Full fund details
- Objective
- Tracks the price and yield performance of the WisdomTree BioRevolution Index.
- Strategy
- Employs a passive management approach to track the WisdomTree BioRevolution Index, investing in equity securities of companies significantly transformed by advancements in genetics and biotechnology. The Fund generally uses a representative sampling strategy and is expected to have significant exposure to the Health Care Sector.
- Inception date
- June 1, 2021
- Fund family
- WisdomTree
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save WDNA to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18